Advertisement
| biologic therapy for ulcerative colitis: Crohn's Disease and Ulcerative Colitis Daniel C. Baumgart, 2017-03-01 This new edition is a unique combined resource for physicians and scientists addressing the needs of both groups. In addition to stimulating exchange and collaboration and shortening the path between discovery and application of new knowledge, the book helps clinicians understand new therapeutic concepts from their origins. The volume serves as a comprehensive guide to the current diagnostic modalities, including enhanced imaging techniques such as MRI and CT enterography, virtual colonoscopy, ultrasound, and endomicroscopy, as well as conventional and complex immunomodulatory principles. The latest edition also includes revised chapters from the previous edition, as well as new chapters reflecting current developments in the field. Written by experts in their field, Crohn’s Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach, Second Edition is of great value to gastroenterologists, surgeons, internists, pediatricians and gynecologists trainees, as well as all those involved in Crohn’s disease, ulcerative colitis, and related autoimmune disorders. |
| biologic therapy for ulcerative colitis: Treatment of Inflammatory Bowel Disease with Biologics Adam S. Cheifetz, Joseph D. Feuerstein, 2017-11-09 This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn’s disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease. |
| biologic therapy for ulcerative colitis: Advances in Inflammatory Bowel Diseases P. Rutgeerts, J-F. Colombel, S.B. Hanauer, J. Schölmerich, Guido Tytgat, A. van Gossum, 1998-12-31 Ulcerative colitis and Crohn's disease remain a great therapeutic challenge to the medical community. In recent years knowledge about the pathogenesis of these diseases has progressed rapidly but the cause of the diseases remains completely unknown. It has become clear that dysregulation of the mucosal immune system is the basis for the chronic evolution of the diseases in a genetically susceptible population. Exciting new therapeutic approaches have been attempted in the last couple of years and cytokine and anti-cytokine treatments in particular seem very promising, especially in intractable disease. The format of the Falk Symposium 106 on `Advances in Inflammatory Bowel Diseases', held in Brussels, Belgium, June 18-20, 1998, was somewhat innovative as each session attempted to link the new insights into pathogenetic mechanisms with new therapeutic approaches, resulting in optimal information transfer. The classic therapeutic schemes were updated with a special focus on step-wise build-up of therapy. |
| biologic therapy for ulcerative colitis: Harrison's Principles of Internal Medicine Tinsley Randolph Harrison, 1998 Classic text for practitioners, residents, and students. |
| biologic therapy for ulcerative colitis: Biologics in Inflammatory Bowel Disease Scott Plevy Associate Professor of Medicine Division of Gastroenterology, 2010 SERIES OVERVIEW: The Oxford American Pocket Notes are a series of ultra-concise, small-format books for healthcare professionals on topics related to the diagnosis, treatment and management of various medical conditions. Each title typically features an outline of key points, guidelines and tools such as patient assessments and treatment algorithms, for a specific area of medical diagnosis and/or management. Highly practical in format, content and style, the Pocket Notes serve as a quick, easily accessible point-of-care reference for busy practitioners. In effect, they are miniature versions of the Oxford American Medical Library and Oxford American Handbooks in Medicine, capturing the key essentials needed for appropriate assessment and treatment. Inflammatory bowel disease (IBD) is a gastrointestinal condition which causes inflammation of the lining of the digestive tract. This disease affects an estimated one million Americans, usually in the forms of ulcerative colitis (UC) and Crohn's disease (CD). These two diseases have similar symptoms and are often confused for one another. Crohn's disease can occur anywhere in the digestive tract, often spreading deep into the layers of affected tissues, but ulcerative colitis usually affects only the innermost lining (mucosa) of the large intestine and rectum. IBD patients suffer from severe diarrhea and abdominal pain, and may experience other complications, such as arthritis and kidney stones, that affect the body beyond the intestinal tract. The Oxford American Pocket Notes: Biologics in Inflammatory Bowel Disease is a practical guide to the safe administration of biological agents to treat inflammatory gastrointestinal illnesses. This ultra-concise and practical volume focuses on tumor necrosis factor (TNF) blocking therapy (TNF blocker), an important new class of biologic therapy indicated for the treatment of several rheumatic and other auto-immune disorders, including Crohn's disease and ulcerative colitis. This uniquely compact and affordable book features evidence-based discussion and guidelines on the mechanism of action, dosing, administration and safety considerations for the biologic agents approved to treat CD and UC, thus providing practicing physicians with easily accessible tools and insights on the use of these drugs in a daily practice setting. Culled from the pages of Handbook of Biological Therapy, this portable guide is a valuable resource for gastroenterologists, primary care physicians and other healthcare providers involved in the management of these chronic but treatable diseases. |
| biologic therapy for ulcerative colitis: Safe and Effective Medicines for Children Institute of Medicine, Board on Health Sciences Policy, Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), 2012-10-13 The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children. |
| biologic therapy for ulcerative colitis: Coping with Crohn’s and Colitis Melissa G. Hunt, 2021-11-11 This practical guide provides patients who have inflammatory bowel disease (IBD) with cognitive-behavioral therapy (CBT) strategies for coping with IBD. It teaches a number of skills that can make coping with Crohn’s or colitis easier. Chapters provide an overview of Crohn’s and colitis as well as the interplay between stress and the gut, before offering strategies on relaxation training, physical activity, managing stress and avoidance, diet and nutrition, and medical treatment options. The book also emphasizes the importance of the doctor-patient relationship and helps patients learn how to think about medical management (including the possibility of surgery) to minimize anxiety from catastrophic thoughts and balance potential risks and benefits appropriately. Dr. Hunt challenges readers to engage in specific behavioral experiments to reduce shame and stigma and highlights practical applications with case illustrations and clinical vignettes. This book can be used as a standalone self-help book or in conjunction with practitioners during in-person therapy. |
| biologic therapy for ulcerative colitis: Adverse Reactions to Biologics L. Puig, W. Gulliver, 2017-11-07 In many areas of medicine physicians still face the great challenge of finding therapies that will meet the patients’ needs. In dermatology the challenge has arisen on multiple fronts through advances in the understanding of the immunopathogenesis of many inflammatory and malignant cutaneous disorders. Breakthroughs, combined with significant developments in targeted immunotherapy, have resulted in improved outcomes as these newer therapies are being used for both approved indications and as off-label therapies for various chronic inflammatory skin disorders and many forms of skin cancer. In the expectation that by truly understanding the safety profile of these targeted therapies patients’ outcomes will be significantly improved, this book offers insights into topics such as adverse reactions, infectious complications and the perioperative use of biologics in psoriasis, immunogenicity of biologic therapies, paradoxical reactions, safety of biologics used to treat autoimmune bullous diseases and primary cutaneous lymphomas, adverse reactions and skin manifestations of therapies targeting melanoma and non-melanoma skin cancer and other neoplastic diseases. Eminent researchers with extensive clinical experience have contributed to this publication, providing an in-depth overview of the latest knowledge in this field. |
| biologic therapy for ulcerative colitis: Pediatric Inflammatory Bowel Disease Petar Mamula, Jonathan E. Markowitz, Robert N. Baldassano, 2012-12-14 Pediatric Inflammatory Bowel Disease, Second Edition provides an essential reference with an emphasis on the unique pediatric issues of IBD. Chapters focus on complications of IBD specific to children and adolescents. Treatment recommendations are based on the latest clinical research available. The textbook also presents sections dedicated to the aspects of participation in clinical research unique to children and adolescents and the complicated yet vital process of successfully transitioning a patient from a pediatric to adult specialist. Controversies in pediatric IBD care such as the off-label use of medications are also covered. The format incorporates multiple tables, graphs, and figures to improve readability and make for an efficient reference for clinicians to use. Thoroughly revised and updated from the first edition, the volumes includes new therapies that are currently being used or tested for treatment of IBD, important areas regarding incidence and prevalence, immunization and response to vaccine administration as well as advancements in our understanding of growth and development with particular to the use of growth hormone therapy. Other new areas covered include important topics of complementary and alternative medicine use in IBD, immunization, and liver disease in IBD. Pediatric Inflammatory Bowel Disease, Second Edition is a valuable resource for pediatric gastroenterologists as well as adult gastroenterologists. |
| biologic therapy for ulcerative colitis: Biologics, Biosimilars, and Biobetters Iqbal Ramzan, 2021-02-03 A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective. Explains what pharmacists need to discuss the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients about Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists |
| biologic therapy for ulcerative colitis: Inflammatory Bowel Disease Stephan R. Targan, Fergus Shanahan, Loren C. Karp, 2011-08-24 This is the state-of–the-art book on inflammatory bowel disease you have been waiting for Written and edited by international experts in gastroenterology this up-to-date volume provides a complete review of the basic science behind inflammatory bowel disease (IBD), as well as evidence-based clinical guidance on diagnosis, treatment and long-term management of IBD. In 50 chapters the authors cover the latest and most promising treatment modalities and the science behind them. There are chapters which cover the advances in the medical and surgical treatment of conditions such as Crohn's disease and ulcerative colitis, as well as chapters focusing on nutrition, imaging and complementary medicine. This is an invaluable information resource for all those in the medical team treating patients with IBD. Whether you are a gastroenterologist, gastrointestinal surgeon or GI nurse specialist this book deserves a place in your library. |
| biologic therapy for ulcerative colitis: Pharmacoepidemiology Brian L. Strom, Stephen E. Kimmel, Sean Hennessy, 2019-12-16 Dieses Lehrbuch, ein wegweisender Klassiker, bietet in der 6. Auflage noch mehr Inhalte für Leser, die aktuelle Informationen zur Pharmakoepidemiologie benötigen. Die vorliegende Auflage wurde vollständig überarbeitet und aktualisiert. Sie bietet einen Überblick über sämtliche Facetten des Fachgebiets, aus Sicht von Lehre und Forschung, aus Sicht der Industrie und von Regulierungsbehörden. Datenquellen, Anwendungen und Methodiken werden verständlich erläutert. |
| biologic therapy for ulcerative colitis: Decision Modelling for Health Economic Evaluation Andrew Briggs, Mark Sculpher, Karl Claxton, 2006-08-17 In financially constrained health systems across the world, increasing emphasis is being placed on the ability to demonstrate that health care interventions are not only effective, but also cost-effective. This book deals with decision modelling techniques that can be used to estimate the value for money of various interventions including medical devices, surgical procedures, diagnostic technologies, and pharmaceuticals. Particular emphasis is placed on the importance of the appropriate representation of uncertainty in the evaluative process and the implication this uncertainty has for decision making and the need for future research. This highly practical guide takes the reader through the key principles and approaches of modelling techniques. It begins with the basics of constructing different forms of the model, the population of the model with input parameter estimates, analysis of the results, and progression to the holistic view of models as a valuable tool for informing future research exercises. Case studies and exercises are supported with online templates and solutions. This book will help analysts understand the contribution of decision-analytic modelling to the evaluation of health care programmes. ABOUT THE SERIES: Economic evaluation of health interventions is a growing specialist field, and this series of practical handbooks will tackle, in-depth, topics superficially addressed in more general health economics books. Each volume will include illustrative material, case histories and worked examples to encourage the reader to apply the methods discussed, with supporting material provided online. This series is aimed at health economists in academia, the pharmaceutical industry and the health sector, those on advanced health economics courses, and health researchers in associated fields. |
| biologic therapy for ulcerative colitis: Endoscopy in Inflammatory Bowel Disease Richard Kozarek, Michael Chiorean, Michael Wallace, 2014-11-03 This book conjoins the latest advances on the use of endoscopy to diagnose, monitor, and treat patients with inflammatory bowel disease. Chapters include the historical use of rigid sigmoidoscopy, non-interventional imaging procedures, and the correlation of pathology and endoscopic visualization. This is the first book to include individual chapters in gastroenterology, colorectal surgery, and IBD texts, the preeminent role of endoscopic imaging in the management of chronic ulcerative colitis, and Crohn's disease. It also includes chapters on capsule endoscopy and balloon and overtube-assisted enteroscopy to define the presence and activity of Crohn's enteritis and additional chapters defining the use of random biopsies versus chromoendoscopy, and computer enhanced imaging to define possible dysplasia development. The book also includes access to online videos, making it the ultimate verbal and visual tool for all medical professionals interested in the advances in the field over the last several decades. Endoscopy in Inflammatory Bowel Disease is a concise text that is of great value to practicing endoscopists, gastroenterologists, general or colorectal surgeons, physicians in training, and all medical professionals caring for patients with inflammatory bowel disease. |
| biologic therapy for ulcerative colitis: Vitiligo Somesh Gupta, Dr. Mats J. Olsson, Dr. Davinder Parsad, Henry W. Lim, Nanja van Geel, Amit G. Pandya, 2018-04-30 Practical guidance based on expert experience and evidence for developing management strategies for vitiligo This complete guide to vitiligo provides a full appraisal of strategy for the treatment of this autoimmune disease that affects 1-2% of the world’s population. It addresses all aspects of vitiligo, covering the science, medical and surgical therapies, and the psychological evaluations and approaches based on the proper understanding of the causes and classification of a particular case. Management of vitiligo is challenging and requires a multipronged approach. Vitiligo: Medical and Surgical Management is a comprehensive, timely, state-of-the-art resource that will help those involved with affected patients better understand and treat this disease, which takes its toll on the mental wellness of those afflicted by it. It takes an evidenced-based approach to the disease’s treatment; provides an overview of the surgical management; covers tissue and cellular grafting; and more. Thoroughly guides those involved in the clinical aspects of vitiligo Aids diagnosis and classification of severity Balances evidence and experience Compiled by world-leading expert editors Comprehensive in nature, Vitiligo: Medical and Surgical Management contains a strong practical element, and is a welcome go-to source for practicing dermatologists and those training to become a dermatologist. |
| biologic therapy for ulcerative colitis: Evidence-Based Medicine Toolkit Carl Heneghan, Douglas Badenoch, 2013-05-06 This bestselling pocket guide to the skills of evidence-basedmedicine succeeds in demystifying the terminology and processes ina handy and easy-to-follow format, all within the space of 100pages. With an improved layout, this second edition ofEvidence-based Medicine Toolkit offers more up-to-dateguidance as well as new sections on important areas ofresearch. New features of this second edition include: A box for each major database showing how to search theevidence, and highlighting the differences between them Flow charts for different study types New critical appraisal sections on qualitative research andeconomic evaluation Expanded list of EBM resources on the net. With these added features to make the job easier, the newToolkit is now an even better companion for all health careprofessionals using evidence-based methodology in their researchand practice. |
| biologic therapy for ulcerative colitis: Therapeutic Immunosuppression Angus W. Thomson, 2001 This work has broad applications in clinical medicine, ranging from prevention and treatment of organ and bone marrow transplant rejection, management of various autoimmune disorders (for example, rheumatoid arthritis), skin disease and asthma. Whereas traditionally only a small repertoire of immunosuppressive agents was available for clinical use, recent discoveries have significantly increased the number of approved agents, resulting in numerous trials to further evaluate their potential. There is also considerable interest in the potential of cell-based therapies (particularly hematopoietic stem and dendritic cell therapy) of allo- and autoimmunity. Important recent advances in the immunotherapy of allergic diseases are also covered in this book. This volume is intended both for practising physicians and surgeons and for biomedical scientists at the graduate/postdoctoral levels, and is designed to provide the theory behind these various approaches to immunosuppression, and to provide state-of-the-art reviews of current developments in each area. |
| biologic therapy for ulcerative colitis: Current Medical Treatment Cyril William Holmes Havard, 1976 |
| biologic therapy for ulcerative colitis: Earthing Clinton Ober, Stephen T. Sinatra, Martin Zucker, 2010 The solution for chronic inflammation, regarded as the cause of the most common modern diseases, has been identified! Earthing introduces the planet's powerful, amazing, and overlooked natural healing energy and how people anywhere can readily connect to it. This never-before-told story, filled with fascinating research and real-life testimonials, chronicles a discovery with the potential to create a global health revolution. |
| biologic therapy for ulcerative colitis: Moderate to Severe Psoriasis John Koo, Jashin Wu, Alice Gottlieb, Ethan Levin, Argentina Leon, 2014-03-18 Written by experts in the dermatology field, this new fourth edition of Moderate-to-Severe Psoriasis discusses the current use of biologics and other pharmacologic and phototherapy treatments for moderate-to-severe psoriasis. Illustrated with high quality color figures, this standalone text emphasizes safe and effective treatments for the psoriasis |
| biologic therapy for ulcerative colitis: Biologic Therapy for Inflammatory Bowel Diseases Daniel C. Baumgart, 2010 |
| biologic therapy for ulcerative colitis: Therapy for Severe Psoriasis E-Book Jashin J. Wu, Steven R. Feldman, Mark Lebwohl, 2016-12-02 A brand-new title in the field of dermatology, Therapy for Severe Psoriasis provides the ultimate coverage of the treatment options available for today's most serious cases, including biologics and oral therapies. It features discussions of the newest drug therapies, recent FDA-approved biosimilars, and combination approaches to care, while an overview chapter was designed to aid those new to the field in understanding the nuances of difficult-to-treat subtypes of psoriasis. Comprehensive and focused, Therapy for Severe Psoriasis will be a welcome addition to the library of any dermatologist seeking in-depth information on the challenges of this condition. - Each of the 16 chapters includes either an in-depth focus on a single therapy or an overview of a unique aspect of psoriasis, including: UVB therapy, methotrexate, acitretin, cyclosporine, apremilast, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab. - Takes an evidence-based approach to hard-to-treat severe psoriasis. - Discusses the newest drug therapies (such as ixekizumab), plus recent FDA-approved biosimilars, a topic unique to this particular psoriasis text. - Presents combination approaches for instances when standard treatments are not successful. - Includes an overview chapter to help beginners understand the nuances of the disorder. |
| biologic therapy for ulcerative colitis: Personalizing Treatment In IBD: Hype or Reality In 2020? Fernando Gomollón, Edouard Louis, 2021-07-05 |
| biologic therapy for ulcerative colitis: Nutrition Guide for Clinicians Neal D. Barnard, Rick Weissinger, MS, Brent J. Jaster, MD, 2009 Designed by medical professionals, this manual is a comprehensive, portable medical reference that covers nearly one hundred diseases and conditions, including risk factors, diagnoses, and typical treatments. Most importantly, it provides the latest evidence-based information on nutrition's role in prevention and treatment. |
| biologic therapy for ulcerative colitis: WHO consolidated guidelines on tuberculosis. Module 2 World Health Organization, 2021-03-22 The WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease is an updated and consolidated summary of WHO recommendations on systematic screening for tuberculosis (TB) disease, containing 17 recommendations for populations in which TB screening should be conducted and tools to be used for TB screening. TB screening is strongly recommendations for household and close contacts of individuals with TB, people living with HIV, miners exposed to silica dust, and prisoners. In addition, screening is conditionally recommended for people with risk factors for TB attending health care, and for communities with risk factors for TB and limited access to care (e.g. homeless, urban poor, refugees, migrants). General population screening is recommended in high-burden settings (0.5% prevalence or higher). Symptoms, chest radiography (CXR), and molecular WHO-recommended rapid diagnostic tests for TB are recommended as screening tools for all adults eligible for screening. Computer-aided detection programmes are recommended as alternatives to human interpretation of CXR in settings where trained personnel are scarce. For people living with HIV, C-reactive protein is also a good screening tool. This guideline document is accompanied by an operational handbook, the WHO operational handbook on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease, that presents principles of screening, steps in planning and implementing a screening programme, and algorithm options for screening different populations. |
| biologic therapy for ulcerative colitis: The Essential RBRVS Ingenix, 2009 |
| biologic therapy for ulcerative colitis: Curbside Consultation in IBD David T. Rubin, Sonia Friedman, Francis A. Farraye, 2009 Are you looking for concise, practical answers to questions that are often left unanswered by traditional IBD references? Are you seeking brief, evidence-based advice for complicated cases or complications? Curbside Consultation in IBD: 49 Clinical Questions provides quick and direct answers to the thorny questions commonly posed during a curbside consultation between colleagues. Dr. David Rubin, Dr. Sonia Friedman and Dr. Francis A. Farraye have designed this unique reference, which offers expert advice, preferences, and opinions on tough clinical questions commonly associated with IBD. The unique Q&A format provides quick access to current information related to IBD with the simplicity of a conversation between two colleagues. Numerous images, diagrams, and references are included to enhance the text and to illustrate IBD. Curbside Consultation in IBD: 49 Clinical Questions provides information that high-volume clinicians will appreciate, and yet is basic enough for residents. Gastroenterologists, fellows and residents in training, surgical attendings, and surgical residents will benefit from the user-friendly and casual format and the expert advice contained within. Some of the questions that are answered: - Which patients might be better for a top down approach (using anti-TNF therapy before steroids or proven failure of oral thiopurines)? What clinical behavior or serological markers might you use to identify these patients? - When is it appropriate to switch to another biologic therapy? - Should I be using chromoendoscopy in my surveillance colonoscopy in IBD? How and which agent? Would narrow band imaging be an alternative for this? - Can we follow flat low-grade dysplasia? Is any dysplasia really flat or just a spectrum of depth and size? - If women continue infliximab therapy during pregnancy, what are the implications for the baby? What should we be telling our patients about vaccinations? |
| biologic therapy for ulcerative colitis: Mild to Moderate Psoriasis John Y. M. Koo, Ethan C. Levin, Argentina Leon, Jashin J. Wu, Mark G. Lebwohl, 2014-03-18 Using a practical and problem-focused approach, this updated, full-color Third Edition of Mild-to-Moderate Psoriasis equips dermatologists, internists, family practitioners, and residents with a state-of-the-art guide to the clinical management of mild-to-moderate psoriasis.Written by an international team of key opinion leaders, this resource explores new developments in treatments for the condition and provides clinicians with up-to-date strategies for optimal patient management. |
| biologic therapy for ulcerative colitis: Breastfeeding and Medication Wendy Jones, 2018-05-11 Sadly, women often feel they have no alternative but to give up breastfeeding, having been prescribed or purchased medication. In many cases, however, this is unnecessary. This book outlines the evidence base for the use of medication during breastfeeding. Breastfeeding and Medication presents a comprehensive A to Z guide to the most frequently prescribed drugs and their safety for breastfeeding mothers. Evaluating the evidence for interventions and using a simple format for quickly identifying medications that are safe or unsafe to use, it also highlights those drugs where there is inconclusive evidence. Additional contextual information makes this the most complete text for those practitioners who support and treat breastfeeding women. It: provides an overview of the anatomy and physiology of the breast together with hormonal influences to better understand how complications, such as mastitis, arise and inform the approach to their treatment; includes a section on conditions that affect women specifically when they are lactating where prescription of medication may be necessary; discusses the importance of breastfeeding and its advantages, as well as its disadvantages; and explores how to support breastfeeding mothers, and presents a counselling model approach. This new edition contains information on more drugs and a chapter on the management of some chronic conditions which may affect breastfeeding mothers. In most cases there are options to support the mother’s optimal care whilst allowing her to continue to breastfeed her baby as long as she wishes. This is a topic which raises many questions on social media, which informed the choice of conditions to consider. This is an invaluable reference for all health practitioners and volunteers who work with, support and treat breastfeeding women, including lactation consultants, breastfeeding support workers, health visitors, GPs, practice nurses, pharmacists and midwives. |
| biologic therapy for ulcerative colitis: Clinical Practice Guidelines We Can Trust Institute of Medicine, Board on Health Care Services, Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, 2011-06-16 Advances in medical, biomedical and health services research have reduced the level of uncertainty in clinical practice. Clinical practice guidelines (CPGs) complement this progress by establishing standards of care backed by strong scientific evidence. CPGs are statements that include recommendations intended to optimize patient care. These statements are informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options. Clinical Practice Guidelines We Can Trust examines the current state of clinical practice guidelines and how they can be improved to enhance healthcare quality and patient outcomes. Clinical practice guidelines now are ubiquitous in our healthcare system. The Guidelines International Network (GIN) database currently lists more than 3,700 guidelines from 39 countries. Developing guidelines presents a number of challenges including lack of transparent methodological practices, difficulty reconciling conflicting guidelines, and conflicts of interest. Clinical Practice Guidelines We Can Trust explores questions surrounding the quality of CPG development processes and the establishment of standards. It proposes eight standards for developing trustworthy clinical practice guidelines emphasizing transparency; management of conflict of interest ; systematic review-guideline development intersection; establishing evidence foundations for and rating strength of guideline recommendations; articulation of recommendations; external review; and updating. Clinical Practice Guidelines We Can Trust shows how clinical practice guidelines can enhance clinician and patient decision-making by translating complex scientific research findings into recommendations for clinical practice that are relevant to the individual patient encounter, instead of implementing a one size fits all approach to patient care. This book contains information directly related to the work of the Agency for Healthcare Research and Quality (AHRQ), as well as various Congressional staff and policymakers. It is a vital resource for medical specialty societies, disease advocacy groups, health professionals, private and international organizations that develop or use clinical practice guidelines, consumers, clinicians, and payers. |
| biologic therapy for ulcerative colitis: Dietary Interventions in Gastrointestinal Diseases Ronald Ross Watson, Victor R Preedy, 2019-01-10 Dietary Interventions in Gastrointestinal Diseases: Foods, Nutrients and Dietary Supplements provides valuable insights into the agents that affect metabolism and other health-related conditions in the gastrointestinal system. It provides nutritional treatment options for those suffering from gastrointestinal diseases including Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis and Allergies, among others. Information is presented on a variety of foods, including herbs, fruits, soy and olive oil, thus showing that changes in intake can change antioxidant and disease preventing non-nutrients and affect gastrointestinal health and/or disease promotion. This book serves as a valuable resource for biomedical researchers who focus on identifying the causes of gastrointestinal diseases and food scientists targeting health-related product development. - Provides information on agents that affect metabolism and other health-related conditions in the gastrointestinal tract - Explores the impact of composition, including differences based on country of origin and processing techniques to highlight compositional differences and their effect on the gastrointestinal tract - Addresses the most positive results from dietary interventions using bioactive foods to impact gastrointestinal diseases, including reduction of inflammation and improved function of organs |
| biologic therapy for ulcerative colitis: Drug-Induced Liver Injury , 2019-07-13 Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series |
| biologic therapy for ulcerative colitis: Prognostic Factors in Cancer Paul Hermanek, 1995 |
| biologic therapy for ulcerative colitis: Treatment of Non-infectious Uveitis Phoebe Lin, Eric Suhler, 2019-09-12 This unique, comprehensive book provides a much-needed reference on the treatment and management of non-infectious uveitis. Carefully designed, Treatment of Non-infectious Uveitis is the first book of its kind to provide an in-depth, clinically-relevant, expert-driven resource for ophthalmologists focusing on modalities of uveitis treatment, their mechanism of action, dosing, and side effects. Each chapter provides an introduction, mechanism of action, indication, dosage, side effects, and efficacy summaries from clinical trials and other published literature. Topics range from topical treatment, to locally administered therapy including drug-releasing implants, to systemic immunosuppressive treatments both tried and new, as well as surgical management, with each chapter highlighting important practice pearls as well as easy-reference dosing tables, side effects, and lab monitoring pertinent to the agents discussed. The book concludes with a discussion of novel approaches to the treatment of non-infectious uveitis, and special considerations when treating uveitis in the pediatric patient. The majority of patients with non-infectious uveitis are treated by comprehensive ophthalmologists, many of whom are less familiar with established treatment guidelines outlining the role of corticosteroids and immunomodulatory therapy. While the non-specialist, resident, or fellow is sure to benefit from this one-stop guide to uveitis treatment, retina and uveitis specialists alike will also appreciate the practice tips and thorough coverage of this expertly-written reference. Treatment of Non-infectious Uveitis is the ideal reference for all ophthalmologists who seek to improve their understanding of the causes of uveitis and learn how to best treat this condition. |
| biologic therapy for ulcerative colitis: Mechanisms of Intestinal Inflammation R. Duchmann, 2004-04-30 In recent years considerable progress has been achieved in regard to our understanding of the induction and modulation of the immune response in the intestinal mucosa. It is clear that this mucosal immune reaction is predominantly steered by certain T-cell populations, which are characterized by their cytokine secretion profile. Less well known are the conditions under which the uptake and processing of a specific antigen leads to a certain immune response, whether it be protective, tolerant or inflammatory. However, here again distinct progress has been made in our understanding. Equally significant for immune regulation in the gut appears to be so-called innate immunity. Every shift of equilibrium in the highly regulated mucosal immune reaction is accompanied by an inflammatory reaction and destruction of the mucosa. In nearly all cases, this inflammatory response is dependent on the presence of bacterial intestinal flora. This book, the proceedings of Falk Symposium 133 on Mechanisms of Intestinal Inflammation: Implications for Therapeutic Intervention in IBD', held in Berlin, Germany, on 10-11 June 2003, summarizes present knowledge in the area of unspecific and specific immune reactions in the gut, recording the gaps in our knowledge and, in particular, presenting the possibilities of targeted intervention. The link to inflammatory bowel diseases - Crohn's disease and ulcerative colitis - is always in focus. Chapters by an international panel of basic scientists, clinical researchers and clinicians also record the problems which can originate through today's possible modulation of the immune reaction, setting the basis for review of clinical problems. This book is valuable readings for all scientists and physicians, who, from different perspectives, have an interest in research on IBD and in the clinical management of these diseases. |
| biologic therapy for ulcerative colitis: Biological Therapy for Inflammatory Bowel Disease Raquel Franco Leal, Tristan Torriani, 2020-03-11 The treatment of inflammatory bowel disease (IBD) has posed a major challenge since its appearance. Biomedical researchers, physicians, gastroenterologists, and surgeons have struggled to improve the quality of life of their patients and have sought, above all else, to keep the disease under remission for as long as possible. Blockers for tumoral necrosis factor alpha (TNF-alpha) were the first biological drugs to be discovered and for this reason they played a crucial role in the subsequent evolution of IBD treatment. The aim of this book is to provide an overview of such drugs and the latest developments in IBD immunopathology. Our contributors discuss the main indications, efficacy, and possible side effects of the different types of drugs available today for IBD treatment. |
| biologic therapy for ulcerative colitis: Advanced Therapy of Inflammatory Bowel Disease: Ulcerative Colitis (Volume 1), 3e Theodore M. Bayless, Professor Theodore M Bayless, 2014-05-14 Rev. ed. of: Advanced therapy of inflammatory bowel disease / [edited by] Theodore M. Bayless, Stephen B. Hanauer. 2001. |
| biologic therapy for ulcerative colitis: Optimizing Advanced Therapies in Ulcerative Colitis Maria Abreu, MD, Jean-Frederic Colombel, MD, 2021-10-15 The educational design of this activity addresses the needs of clinical gastroenterologists and specialist nurse practitioners and physician assistants involved in the treatment of patients with ulcerative colitis (UC). |
| biologic therapy for ulcerative colitis: Crohn's Disease and Ulcerative Colitis Fredric G. Saibil, 2011 Inflammatory bowel disease (IBD) includes two chronic conditions, Crohn's disease and ulcerative colitis. It has remained for too long the secret illness no one wants to admit to having, let alone discuss. One percent of the population has IBD, yet its cause is unknown and there is no known cure. Revised and updated, Crohn's Disease and Ulcerative Colitis is the complete practical guide for anyone dealing with inflammatory bowel disease. Fred Saibil, MD, a renowned expert on IBD, provides the most up-to-date, concise, critical and practical information on the common symptoms and side effects. He describes the normal gastrointestinal system and then explains what specifically goes wrong in those suffering from IBD. Crohn's Disease and Ulcerative Colitis includes important information on: * Why people get IBD, including the hygiene hypothesis, and new genetic data * Diagnostic methods, including enteroscopy, capsule endoscopy, CT, MR, and PET scans * Effects of diet, including foods and food components that can cause diarrhea and gas * Surgical options * The expanding choice of drugs, plus probiotics and prebiotics * Issues specific to children with IBD * Effects on sex, child-bearing and drug usage during pregnancy and breast-feeding * Self-management -- how to help your medical team help you * How to take care of your bones * How to cope with being in hospital. For patients, their relatives and caregivers, Crohn's Disease and Ulcerative Colitis explains the plain facts about this terrible disease, which seriously affects the daily lives of so many. |
| biologic therapy for ulcerative colitis: Selective Immunosuppression Luciano Adorini, 1995 |
Electrochemical Instruments Manufacturer / BioLogic
Trusted for over 40 years by academic and industrial organizations worldwide, BioLogic measurement instruments, including potentiostats, battery cyclers, impedance analyzers, …
Products - BioLogic
BioLogic manufactures a variety of robust and user-friendly, potentiostats for diverse applications, from single-channel potentiostats to bipotentiostats to multichannel potentiostats.
Your new potentiostat: unboxing, setup and settings for your
Mar 28, 2022 · This short, easy-to-follow video series will show you exactly how quickly and easily you can set up your BioLogic potentiostat, using the example of the BioLogic SP-150e (the …
Discover Battery Cyclers - BioLogic
BioLogic ® offers a comprehensive line-up of battery cyclers, designed to support every stage of the battery development cycle through two complementary instrument ranges: Premium and …
What is Electrochemical Impedance Spectroscopy (EIS)? - BioLogic
May 23, 2025 · A leader in Electrochemical Impedance Spectroscopy (EIS) technologies, BioLogic strives to place EIS within every researcher's reach, by making it available on all of …
Battery Cycler brochure - BioLogic
May 19, 2025 · The MPG-200 series is a high-end battery testing system made up of two core configurations. The MPG-2 features 16 independent channels at 100 mA, whereas the MPG …
Discover Potentiostat / Galvanostat - BioLogic
BioLogic potentiostats/galvanostats are designed with modularity in mind, offering a wide range of configurations and optional add-ons and accessories that can be tailored to meet your specific …
Overview: Spectrometer solutions - BioLogic
Details of BioLogic's spectrometer solutions: circular dichroism, High throughput CD Microplate spectropolarimeters and pump-probe spectrometers
VSP-3e Potentiostat - BioLogic
Energy-specific functionality unique to BioLogic includes: Fast CCCV shift (constant current, constant voltage) Stack mode (follow individual elements in the pack) BCD (Battery capacity …
EC-Lab® OEM - BioLogic
This package offers an array of tools that enable seamless integration with proprietary software, giving users precise control over their BioLogic Potentiostat/Galvanostat instruments. Key …
Tofacitinib Is Safe and Effective When Used in Combination …
Combination biologic and small molecule therapy may be an appropriate approach in patients with aggressive disease and partial response to biologic therapy. Such an approach has the …
Ulcerative Colitis Care Pathway - Gastroenterology
Ulcerative Colitis Care Pathway Themistocles Dassopoulos,1 Russell D. Cohen,2 Ellen J. Scherl,3 Ronald M. Schwartz,4 Lawrence Kosinski,5 and Miguel D. Regueiro6 ... should receive …
Fact Sheet - Crohn's & Colitis Foundation
Crohn’s disease and ulcerative colitis. The first doses are given by an intravenous infusion, and then can be taken as an injection under the skin. • Mirikizumab-mrkz (Omvoh™) is a biologic …
Is there an optimal sequence of biologic therapies for …
therapy does not seem to be significantly impacted by prior vedolizumab therapy, and may further suggest the benefit of using vedolizumab as a first-line biologic. As adverse event rates remain …
Fact Sheet - Crohn's & Colitis Foundation
adult patients with moderately to severely active Crohn’s disease or ulcerative colitis who have had an inadequate response to conventional therapy. Adalimumab-fkjp is given as a …
Treatment Pathway for Inflammatory Bowel Disease in adults
Pathway 2: Ulcerative colitis –5ASA pathway Pathway 3: Immunosuppressant to advanced therapy Pathway 4: Advanced therapy pathway (UC and Crohn's) Pathway 4 continued: …
Inflammatory Conditions – Velsipity Prior Authorization Policy
corticosteroids, immunomodulators (e.g., 6-mercaptopurine and azathioprine), or a biologic (e.g., ... therapy for ulcerative colitis. A trial of one biologic also counts as a trial of one systemic …
CROHN’S DISEASE: BIOLOGIC THERAPY - Crohn’s and …
options for Crohn’s Disease and Ulcerative Colitis. What is a Biologic? A biologic is a medication that is made from living cells. They have large, complex molecular structures. Biologic …
Indicators of suboptimal biologic therapy over time in patients …
suboptimal biologic therapy is common among patients with UC and CD, with approximately 90% of patients experiencing at least one indicator of suboptimal biologic therapy within 36 months …
RIOR UTHORIZATION POLICY - Cigna
as a systemic therapy for ulcerative colitis. A trial of one biologic other than the requested drug also counts as a trial of one systemic agent for ulcerative colitis. A biosimilar of the requested …
Mirikizumab in moderately to severely active ulcerative …
Sep 16, 2024 · biologic therapy or Janus kinase inhibitor therapy. In clinical trials, initial therapy with intravenous mirikizumab resolved the symptoms of ulcerative colitis, and maintenance …
Second-Line Biologic Therapy Following Tumor Necrosis …
Second–Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real–World Propensity Score–Weighted Analysis Susanne Ibing,1,2 Judy H. Cho,3 Erwin P. …
Entyvio® (Vedolizumab) Commercial Medical Benefit Drug …
vedolizumab used for induction and maintenance therapy of ulcerative colitis. • Vedolizumab should be compared to other currently approved therapies for ulcerative colitis in these trials. A …
Pharmacological Management of Adult Outpatients With …
Jul 26, 2019 · Adult outpatients with moderate to severely active ulcerative colitis Biologic therapy and tofacitinib Thiopurines and methotrexate Suggest using biologic agents (with or without …
PRESS RELEASE - abbvie.ca
of adults with moderately to severely active ulcerative colitis (UC) who have demonstrated prior treatment failure, i.e., an inadequate response to, loss of response to, or intolerance to at least …
MEDICAL POLICY - TREMFYA IV (GUSELKUMAB) - BCBSM
used in combination with other biologic agents or targeted DMARDs (e.g., Janus kinase (JAK) inhibitors). - Ulcerative colitis - The 2019 ACG guidelines and the 2020 AGA guidelines for …
Inflammatory Conditions Entyvio Intravenous Prior …
Ulcerative colitis, in adults with moderately to severely active disease. Therapy begins with Entyvio 300 mg IV at Week 0 and Week 2. At Week 6, or at any scheduled Entyvio IV infusion …
In the real-world setting, biologic therapy in patients with …
ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR ADALIMUMAB Sumesh Kachroo, Maryia Zhdanava, Sabree Burbage, ... Dominic Pilon BACKGROUND: In the real-world …
GutMicrobiomeFunctionPredictsResponsetoAnti- integrin …
ulcerative colitis (UC) patients initiating anti-integrin therapy (vedolizumab). Disease activity and stool metagenomes at baseline, and weeks 14, 30, and ... biologic therapy has not been …
Ulcerative Colitis: Developing Drugs for Treatment - U.S.
44354222dft_Ulcerative Colitis.docx 4/29/2022 ... For cellular and gene therapy products, there may be additional considerations. ... 75 treatment with a biologic and subjects who have failed ...
University of Michigan - Wicha Lab
b) Metronidazole therapy17 i) If postop plan includes using a Biologic, no need to start metronidazole postoperatively ii) If postop plan does NOT include Biologic therapy, start …
Comparative Efficacy of Biologics and Small Molecule in …
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis Mohammad Shehab,1,2 Fatema Alrashed,2 Abdulwahab …
Perforated Toxic Megacolon: The Dreaded Complication in …
with a new diagnosis of ulcerative colitis that was refractory to corticosteroids and biologic therapy. Early recognition and treatment are crucial to reduce morbidity and mortality …
Treatment Discontinuation in Patients with Ulcerative Colitis …
Adherence to biologic therapies that involve a transition from intravenous (IV) induction to subcutaneous (SC) maintenance can be challenging in patients with ulcerative colitis (UC) or …
A Practical Approach to anaging Inpatient Acute Severe …
In preparation for possible biologic therapy, one should test for tuberculosis (QuantiFERON-TB Gold and chest x-ray), hepatitis B (hepatitis B surface ... Patients with Severe Ulcerative Colitis …
Dosing Crohn’s disease Ulcerative colitis
Ulcerative colitis . In ulcerative colitis (UC), a three-dose induction regimen (1,200 mg at Weeks 0, 4, and 8) is administered by IV infusion. 1 Following induction therapy with the IV product, the …
A systematic review of vitiligo onset and exacerbation in …
receiving biologic therapy To the Editor: Biologic therapies have improved outcomes in patientswith immune-mediated inflam- ... 1.1% of adults with ulcerative colitis and 0.5% of …
Tofacitinib for Biologic-Experienced Hospitalized Patients …
Jun 1, 2021 · BACKGROUND: Despite rescue therapy, more than 30% of patients with acute severe ulcerative colitis (ASUC) require colectomy. Tofacitinib is a rapidly acting Janus kinase …
Innovative Horizons in Ulcerative Colitis Treatment: A 2024 …
The most recent treatments for moderate to severe ulcerative colitis are thoroughly reviewed in the 2024 American Gastroenterological Association Evidence Synthesis. The therapy …
Risankizumab Is Superior to Placebo for Induction and …
Ulcerative Colitis (UC): Assessing the UC Treatment Paradigm IBD Rahul Dalal, MD, MPH ... experienced patients who had a history of inadequate response to biologic therapy. …
Ulcerative Colitis: Use of Biologic Agents and Small …
7.2 Combination Biologic and Immunomodulator Therapy 11 7.3 Biosimilar Medicines 13 8 Dosage Schedules 14 8.1 Infliximab 14 8.2 Adalimumab 16 8.3 Golimumab 17 8.4 …
Anti-interleukin-23 agents for the treatment of ulcerative colitis
Ulcerative colitis (UC) is a chronic relapsing disease of unknown cause characterized by continuous mucosal inflam-mation of the colon leading to substantial morbidity and impaired …
Optimizing biologic therapy in IBD: how essential is ... - Nature
biologic therapy to achieve and maintain clinical and endoscopic remission, and ... Crohn’s disease and ulcerative colitis 18 ,51 52 54. In the 2019 PANTS study, 955 patients
Ustekinumab as Induction and Maintenance Therapy for …
1202 n engl j med 381;13 nejm.orgSeptember 26, 2019 The new england journal of medicine U lcerative colitis is a chronic in-flammatory disease of the large intes-tine.1,2 Current therapies …
Earlier Anti-TNF Initiation Leads to Long-term Lower Health …
BACKGROUND & AIMS: The timing of initiating biologic therapy in persons with Crohn’s disease (CD) and ulcerative colitis (UC) is an area of ongoing controversy. In particular, there is …
Biologic therapy for ulcerative colitis associated with immune ...
Biologic therapy for ulcerative colitis associated with immune thrombocytopenia Manabu Nagayama1,3 · Yohei Funayama 1 · Osamu Taniguchi1 · Kaoru Hatano2 · Kunihiko Oguro1 · …
NHS Lanarkshire Outpatient IBD Treatment Pathway …
with a confirmed diagnosis of Ulcerative Colitis in the outpatient secondary care setting in NHS Lanarkshire. • The pathway provides a stepwise approach to the management of Ulcerative …
Indicators of suboptimal biologic therapy over time in patients …
This study assessed the occurrence of indicators for suboptimal biologic therapy among ulcerative colitis (UC) and Crohn’s disease (CD) patients over time in the United States
RIOR UTHORIZATION POLICY - Cigna
does not count as a systemic therapy for ulcerative colitis. A trial of one biologic also counts as a trial of one systemic agent for ulcerative colitis. Refer to the Appendix A for examples of …
SYSTEMATIC REVIEWS AND META-ANALYSES - Clinical …
severe ulcerative colitis (Mayo Clinic score of 6–12, with an endoscopic subscore of 2 or 3) who were either treatment-naïve (first-line) or previously exposed to TNFa antagonists (second …
Filgotinib as induction and maintenance therapy for …
for ulcerative colitis. We searched PubMed with the terms “ulcerative colitis”, “treatment”, and “moderate to severe” to identify articles in English published from Jan 1, 2016, to Nov 1, 2020. …
Mirikizumab for treating moderately to severely active …
Ulcerative colitis treatment pathway Inadequate response to biologic therapy / TNF-α contraindicated only: IR/intolerant to CT: IR/intolerant to CT or biologic: S1P receptor …
A Systematic Review of the Economic and Health-Related
ere ulcerative colitis that can reduce healthcare costs, use of healthcare resources, and effect on society. Keywords: Ulcerative colitis; Biologic therapy; Systematic literature review; Direct …
AGA LIVING GUIDELINES: PHARMACOLOGICAL …
112 Ulcerative colitis (UC) affects nearly 2 million individuals in the United States and millions more ... 119 first biologic therapy (infliximab) for UC in 2005, there have been ten additional …
ISG 236006 Summer 2025 - isge.ie
conventional therapy or a biologic therapy. Ulcerative colitis: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, …
PGI9 Cost-Effectiveness Comparison of Vedolizumab, …
imab (IFX) and conventional therapy (CVT) for treating moderately to severely active Ulcerative Colitis (UC) patients who are naïve to biologic treatments. Methods: A Markov decision model …
Biologic Therapy of Inflammatory Bowel Disease
biologic therapies that mechanistically target individual inflammatory pathways. Many biologic therapies are be-ing evaluated for the treatment of the chronic inflam-matory bowel diseases, …
Ozanimod as Induction and Maintenance Therapy for …
Ozanimod Therapy for Ulcerative Colitis U lcerative colitis is a chronic dis-ease that is characterized by a dysregulated immune response and chronic inflam-mation in the colonic …
Ozanimod: A Review in Ulcerative Colitis - Springer
Aug 3, 2022 · ulcerative colitis in the USA [11], and in adults with moderately to severely active ulcerative colitis who have had an inadequate or lost response to, or were intolerant of, either …
S44 Gastroenterology Vol. 156, No. 3S
patients with an IMD on biologic therapy compared to younger biologic users. Figure 2. Forest plot of pooled malignancy risk among older patients with an IMD on biologic therapy compared to …
